APBCS E-BROCHURE 8 - 10 JANUARY, 2021 ACCESS VIRTUAL PLATFORM VIRTUAL SUMMIT
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
8 - 10 JANUARY, 2021
VIRTUAL SUMMIT
ACCESS
VIRTUAL PLATFORM
APBCS E-BROCHURE
ORGANIZED BY
APBCS.ORG
1
TABLE OF
CONTENT
Organizing & Scientific Committee 3
International Speakers 4
Regional Speakers 7
Local Speakers 9
Program at Glance 12
Best of San Antonio Breast Cancer
Symposium Program 13
Oncology Nursing Session 15
APBCS Agenda - Day 1 16
APBCS Agenda - Day 2 18
Sponsors 23
2
ORGANIZING COMMITTEE
SHAHEENAH DAWOOD REBECCA DENT LEE SOO CHIN
UAE SINGAPORE SINGAPORE
SCIENTIFIC COMMITTEE
SHAHEENAH DAWOOD REBECCA DENT LEE SOO CHIN
UAE SINGAPORE SINGAPORE
NAN SOON WONG GEOK HOON LIM MAY LENG MABEL TAN
SINGAPORE SINGAPORE SINGAPORE
3
INTERNATIONAL SPEAKERS
ADAM BRUFSKY
ASSOCIATE CHIEF, DIVISION OF HEMATOLOGY/ONCOLOGY DIRECTOR,
COMPREHENSIVE BREAST CANCER CENTER UNIVERSITY OF PITTSBURGH
SCHOOL OF MEDICINE
USA
ADITYA BARDIA
MOLECULAR ONCOLOGIST, MASSACHUSETTS GENERAL HOSPITAL
USA
CHARLES PEROU
PROFESSOR, LINEBERGER COMPREHENSIVE CANCER CENTER
USA
DARCY BURBAGE
ONCOLOGY CLINICAL NURSE, CHRISTIANA CARE HEALTH SYSTEM
USA
EVANDRO DE AZAMBUJA
HEAD OF THE MEDICAL SUPPORT TEAM, JULES BORDET INSTITUTE
BELGIUM
FABRICE ANDRE
MEDICAL ONCOLOGIST, INSTITUT GUSTAVE ROUSSY
FRANCE
4
GIUSEPPE CURIGLIANO
ASSOCIATE PROFESSOR, UNIVERSITY OF MILANO
ITALY
IAN KROP
ASSOCIATE CHIEF DIVISION OF BREAST ONCOLOGY,
DANA FARBER CANCER INSTITUTE
USA
JAVIER CORTES
MEDICAL ONCOLOGIST, HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL
SPAIN
LISA CAREY
PROFESSOR, NORTH CAROLINA CANCER HOSPITAL
USA
MONICA MORROW
SURGICAL ONCOLOGIST, MEMORIAL SLOAN KETTERING CANCER CENTER
USA
NICHOLAS TURNER
CONSULTANT MEDICAL ONCOLOGIST, THE INSTITUTE OF CANCER RESEARCH
UNITED KINGDOM
5
PETER FASCHING
ASSOCIATE PROFESSOR, UNIVERSITY HOSPITAL ERLANGEN AND
COMPREHENSIVE CANCER CENTER
GERMANY
PHILIP POORTMANS
PROFESSOR, CURIE INSTITUTE
BELGIUM
SANDRA SWAIN
ASSOCIATE DEAN FOR RESEARCH DEVELOPMENT, PROFESSOR OF MEDICINE,
GEORGETOWN UNIVERSITY MEDICAL CENTER
USA
SHAHEENAH DAWOOD
MEDICAL ONCOLOGIST, MEDICLINIC CITY HOSPITAL
UNITED ARAB EMIRATES
STEPHEN JOHNSTON
PROFESSOR, THE ROYAL MARSDEN NHS FOUNDATION TRUST
UNITED KINGDOM
6
REGIONAL SPEAKERS
AMY CHOW
ASSOCIATE PROFESSOR, DEPARTMENT OF SOCIAL WORK AND SOCIAL
ADMINISTRATION - THE UNIVERSITY OF HONG KONG
HONG KONG
JANICE TSANG
SPECIALIST IN MEDICAL ONCOLOGY, LI KA SHING FACULTY OF MEDICINE,
THE UNIVERSITY OF HONG KONG
HONG KONG
JYOTI BAJPAI
MEDICAL ONCOLOGIST, TATA MEMORIAL HOSPITAL
INDIA
LU YEN SHEN
CLINICAL PROFESSOR, NATIONAL TAIWAN UNIVERSITY
TAIWAN
SEOCK-AH IM
MEDICAL ONCOLOGIST, SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE
SOUTH KOREA
SHERENE LOI
MEDICAL ONCOLOGIST, PETER MACCALLUM CANCER CENTRE
AUSTRALIA
7
SHOM GOEL
CONSULTANT MEDICAL ONCOLOGIST, PETER MACCALLUM CANCER CENTRE
AUSTRALIA
SHONA NAG
CONSULTANT MEDICAL ONCOLOGIST, DIRECTOR OF ONCOLOGY,
SAHYADRI GROUP OF HOSPITALS
INDIA
VIROTE SRIURANPONG
CHIEF, MEDICAL ONCOLOGY UNIT, CHULALONGKORN UNIVERSITY
THAILAND
YEON HEE PARK
MEDICAL ONCOLOGIST, SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE
SOUTH KOREA
8
LOCAL SPEAKERS
ELAINE LIM
SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
IAIN TAN
MEDICAL ONCOLOGIST, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
JACK CHAN
CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
JOLINE LIM
CONSULTANT, DEPARTMENT OF HAEMATOLOGY-ONCOLOGY,
NATIONAL UNIVERSITY CANCER INSTITUTE
SINGAPORE
LEE SOO CHIN
MEDICAL ONCOLOGIST, NATIONAL UNIVERSITY CANCER INSTITUTE
SINGAPORE
MAY LENG MABEL TAN
ADVANCED PRACTICE NURSE, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
9
REBECCA DENT
SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS
SINGAPORE
SAMUEL OW
CONSULTANT MEDICAL ONCOLOGIST, NATIONAL UNIVERSITY CANCER INSTITUTE
SINGAPORE
TAN PUAY HOON
MEDICAL ONCOLOGIST, SINGAPORE GENERAL HOSPITAL
SINGAPORE
TIRA TAN
CONSULTANT, DIVISION OF MEDICAL ONCOLOGY,
NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
VERONIQUE TAN
HEAD & SENIOR CONSULTANT BREAST SURGERY
NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
WONG NAN SOON
MEDICAL ONCOLOGIST, GLENEAGLES HOSPITAL
SINGAPORE
10YAP YOON SIM
SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
APBCS.ORG
11PROGRAM AT A GLANCE
SINGAPORE DAY ONE DAY TWO DAY THREE
TIME 8th JANUARY, 2021 9th JANUARY, 2021 10th JANUARY, 2021
08:00 GOING LIVE
08:30
09:30
10:30 Oncology Nursing
11:30 Session
12:30
13:00
13:30
14:00
14:00
14:30
15:30 GOING LIVE GOING LIVE GOING LIVE
16:00
16:30 Best of San Antonio
Breast Cancer
17:00 Symposium
17:30
18:00 GOING LIVE
9th Asia-Pacific
18:30 9th Asia-Pacific
Breast Cancer
19:00 Summit Breast Cancer
6th Singapore Summit
19:30 Breast Oncoplastic Day 1
20:00 Surgery Symposium Day 2
(SBOSS)
20:30
21:00
21:30
22:00
22:30
12BEST OF SAN ANTONIO BREAST
CANCER SYMPOSIUM PROGRAM
Friday, 8th January 2021
15.30 - 17.40 Singapore Time
15:30 – 15:40 Topics Presented By:
LIM GEOK HOON, SINGAPORE
Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy
after neoadjuvant chemotherapy in breast cancer: results of the prospective
multicenter RISAS trial
15.40 – 15.45 Q&A
15.45 – 15.55 Topics Presented By:
FAYE LIM, SINGAPORE
Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly):
wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in
women =/> 65 years with early invasive breast cancer:10 year results
A randomized phase III study of radiation doses and fractionation schedules in
non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)
15.55 – 16.00 Q&A
16.00 – 16.20 Topics Presented By:
SHAHEENAH DAWOOD, UAE
Final invasive disease-free survival analysis of monarchE: abemaciclib combined
with adjuvant endocrine therapy for high risk early breast cancer
Phase III study of palbociclib combined with endocrine therapy (ET) in patients
with hormone-receptor-positive (HR+), HER2-negative primary breast cancer
and with high relapse risk after neoadjuvant chemotherapy (NACT): First results
from PENELOPE-B
12 year results of anastrozole versus tamoxifen for the prevention of breast
cancer in postmenopausal women with locally excised ductal carcinoma in-situ
16.20 – 16.25 Q&A
16.25 – 16.35 Topics Presented By:
TIRA TAN, SINGAPORE
Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by
dose-dense EC in high risk HR+/HER2- early BC by: results from the neoadjuvant
part of ADAPT HR+/HER2- trial
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR,
AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-
aTTom Study
16.35 – 16.40 Q&A
1316.40 – 17.05 Topics Presented By:
WONG NAN SOON, SINGAPORE
Adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and
1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy.
Development and validation of a tool integrating the 21-gene recurrence score
and clinicopathlogic features to individualize prognosis for distant recurrence
and prediction of absolute chemotherapy benefit in early breast cancer
How low is low risk: MINDACT updated outcome and treatment benefit in
patients considered clinical low risk and stratified by genomic signature, age and
nodal status
Endocrine therapy alone in patients with intermediate or high-risk luminal early
breast cancer (0-3 lymph nodes), Recurrence ScoreONCOLOGY NURSING SESSION
Saturday, 9th January 2021
8.30 - 13.00 Hrs Singapore Time
08:30 – 08:35 Welcome
MABEL TAN MAY LENG
DNP, RN, ONC, NATIONAL CANCER CENTRE SINGAPORE
08:35 – 09:35 Overview of Breast Cancer Treatment
DARCY BURBAGE
DNP, RN, AOCN, CBCN, CHRISTIANA CARE HEALTH SYSTEM, NEWARK, DELAWARE,
USA
09:35 – 10:05 Management of Breast Cancer Surgical Side Effects
DARCY BURBAGE
DNP, RN, AOCN, CBCN, CHRISTIANA CARE HEALTH SYSTEM, NEWARK, DELAWARE,
USA
10:05 – 10:15 Break
10:15 – 11:15 Psychosocial Challenges and Management of Breast Cancer and Treatments
AMY CHOW
PHD, RSW, FT, THE UNIVERSITY OF HONG KONG, HONG KONG
11:15 – 11:45 Small Group Case Studies Discussion Activity in Breakout Rooms
FACILITATORS
(10 GROUPS)
11:45 – 12:55 Sharing by Small Group Facilitators or Representatives
Comments by Speakers and Participants
MABEL TAN MAY LENG
SINGAPORE
DARCY BURBAGE
USA
AMY CHOW
HONG KONG
12:55 – 13:00 Conclusion & Announcements
MABEL TAN MAY LENG
SINGAPORE
15Saturday, 9th January 2021
15.50 - 21.15 Hrs Singapore Time
APBCS AGENGA – DAY 1
15:50 – 15:55 Opening Remarks
APBCS 2021 COMMITTEE
15:55 – 16:00 Session Introduction - YEON HEE PARK, SOUTH KOREA (Supported by MSD)
16:00 – 16:20 Advances of Immunotherapy in Neoadjuvant TNBC
JAVIER CORTES, SPAIN
16:20 – 16:40 An Asian Perspective with Case studies
YEON HEE PARK, SOUTH KOREA
16:40 – 16:45 Q&A
SESSION 1: ER + Early Breast Cancer
Chairperson: VERONIQUE TAN, SINGAPORE | YAP YOON SIM, SINGAPORE
16:45 – 17:05 Should all ER-pos Patients Receive 10 years of Endocrine Therapy?
STEPHEN JOHNSTON, UK
17:05 – 17:25 Is it time to adopt CDK inhibitors in adjuvant setting? Critical evaluation of the
literature
EVANDRO DE AZAMBUJA, BELGIUM
17:25 – 17:45 Q&A
SESSION 2: Early Breast Cancer
Chairperson: ELAINE LIM, SINGAPORE | SHAHEENAH DAWOOD, UAE
17:45 – 18:05 Special Issues in Young Women with Early Breast Cancer
JYOTI BAJPAI, INDIA
18:05 – 18:25 Personalised breast RT - Are we there yet?
PHILIP POORTMANS, BELGIUM
18:25 – 18:45 What’s New in Surgical Management of the Axilla?
MONICA MORROW, USA
Q&A
16AstraZeneca Symposium 1 - Chairperson: JOLINE LIM, SINGAPORE
18:45 – 18:50 Welcome and Introductions
JOLINE LIM, SINGAPORE
18:50 – 19:05 Evolving role of ADCs in the management of Her2+ mBC
IAN KROP, USA
19:05 – 19:20 Optimizing treatment outcomes while treating Her2+ mBC patients with ADCs
IAN KROP, USA
19:20 - 19:30 Q & A and live discussion
SESSION 3: Neo Adjuvant Therapy
Chairperson: SOO CHIN LEE, SINGAPORE | REBECCA DENT, SINGAPORE
19:30 – 19:50 Tailoring Neoadjuvant / Adjuvant HER2+ Therapy in Breast Cancer
PETER FASCHING, GERMANY
19:50 – 20:10 Tailoring/Neoadjuvant/Adjuvant TNBC Therapy in Breast Cancer
LISA CAREY, USA
20:10 – 20:25 Q&A
Roche Symposium
An Emerging Paradigm in HER2-positive Breast Cancer Treatment
Chairperson: VIROTE SRIURANPONG, THAILAND
20:25 - 20:50 Advancing patient care in HER2-positive breast cancer
SANDRA SWAIN, USA
20:50 - 21:05 Flexible Care: Moving Beyond the Hospital to the Community
LEE SOO CHIN, SINGAPORE
21:05 - 21:10 Q & A and Live Interaction
21:10 Closing Remark
APBCS 2021 COMMITTEE
17Sunday, 10th January 2021
15.55 - 21.45 Hrs Singapore Time
APBCS AGENGA – DAY 2
15:55 – 16:00 Opening Remarks
APBCS 2021 COMMITTEE
Novartis Symposium - Chairperson: LEE SOO CHIN, SINGAPORE
16:00 – 16:15 Transforming Treatment in Pre-menopausal HR+ HER20 ABC: Biological Differences
and the role of CDK4/6i
LU YEN SHEN, TAIWAN
16:15 – 16:30 Personalized Approach to Treatment: Practical Recommendations in Optimizing
Treatment for HR+ HER-2 ABC Patients with PIK3CA Mutation
LU YEN SHEN, TAIWAN
16:30 – 16:45 Q & A and live discussion
SESSION 4: Tumor Biology and Assessment
Chairperson: TIRA TAN, SINGAPORE | IAIN TAN, SINGAPORE
16:45 – 17:05 Liquid Biopsies
NICHOLAS TURNER, UK
17:05 – 17:25 Molecular Profiling for Metastatic Breast Ca- When, How and Why?
FABRICE ANDRE, FRANCE
17:25 – 17:45 What’s on the horizon for new drug development?
GIUSEPPE CURIGLIANO, ITALY
17:45 – 17:50 Q&A
SESSION 5: Molecular Tumor Board
Chairperson: SHAHEENAH DAWOOD, UAE | PAUL MAINWARING, AUSTRALIA
17:50 – 18:30 Tumor Board 1
PANELIST: GIUSEPPE CURLIGLIANO, ITALY | SEOCK-AH IM, SOUTH KOREA |
SHAHEENAH DAWOOD, UAE | SAMUEL OW, SINGAPORE
Pfizer Symposium - Chairperson: SAMUEL OW, SINGAPORE
18:30 – 18:35 Welcome and Introductions
SAMUEL OW, SINGAPORE
18:35 – 18:55 Management of HR+ HER2- mBC: From Clinical Evidence to Real-World Experience
JANICE TSANG, HONG KONG
1818:55 – 19:10 Case Presentation
SHONA NAG, INDIA
19:10 – 19:15 Q & A and live discussion
SESSION 6: Advances in Clinical Management of Metastatic Breast Cancer
Chairperson: JOLINE LIM, SINGAPORE | JACK CHAN, SINGAPORE
19:15 – 19:35 Novel approaches to HER2 + metastatic disease? Where do novel agents fit it?
SEOCK-AH IM, SOUTH KOREA
19:35 – 19:55 Beyond first line CDK inhibition ER + MBC?
SHOM GOEL, AUSTRALIA
19:55 – 20:15 New Therapies in TNBC
ADITYA BARDIA, USA
AstraZeneca Symposium 2 - Chairperson: TIRA TAN, SINGAPORE
20:15 – 20:20 Welcome and Introductions
TIRA TAN, SINGAPORE
20:20 – 20:45 Orchestrating the Sequencing strategies for HR+/Her2- mBC: Lessons learnt in the
decade
ADAM M. BRUFSKY, USA
20:45 – 21:00 Q & A and live discussion
SESSION 7: Interrogating the Immune System in Breast Cancer
Chairperson: SHERENE LOI, AUSTRALIA | REBECCA DENT, SINGAPORE
21:00 – 21:15 Pathologist’s view on how to best to measure PD-L1?
TAN PUAY HOON, SINGAPORE
21:15 – 21:30 New Biomarkers and Models Systems to Discern Sensitivity to Immune Checkpoint
Inhibition
CHARLES PEROU, USA
21:30 – 21:45 What biomarkers do I need to order for my patient with metastatic TNBC and when?
Novel therapies on the horizon for TNBC
SHERENE LOI, AUSTRALIA
21:45 Closing Remark
APBCS 2021 COMMITTEE
19Recommended by International guidelines 1
TECENTRIQ® + NAB-PACLITAXEL
KEEP PATIENTS WITH TNBC
CONNECTED TO LIFE
Updated IMpassion 130 final OS data
TECENTRIQ + nab-paclitaxel: The only cancer immunotherapy in PD-L1 + 1L
mTNBC that demonstrated a clinically meaningful Overall Survival improvement
of 7.5 months2
Test your 1L mTNBC patients for PD-L1 status now
Tecentriq® (Atezolizumab) – Abbreviated Prescribing Information 3
Before prescribing TECENTRIQ®, please consult the full local prescribing information by visiting
www.roche.com.sg/en/pharma/tecentriq.html or by scanning the following QR code.
Therapeutic indications
Non Small Cell Lung Cancer (NSCLC): • TECENTRIQ®, in combination with Avastin, paclitaxel and carboplatin, is indicated for the treatment of patients with metastatic non-squamous NSCLC who had not received prior
chemotherapy. • TECENTRIQ® is indicated for the treatment of patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. • Patients with EGFR or ALK genomic
tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving TECENTRIQ®. • TECENTRIQ®, in combination with nab-paclitaxel and carboplatin is indicated for first line
treatment of patients with metastatic non squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations. Small Cell Lung Cancer (SCLC): • TECENTRIQ® in combination with carboplatin and etoposide, is
indicated for the first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Triple Negative Breast Cancer (TNBC): • TECENTRIQ® in combination with nab-paclitaxel, is indicated for the treatment
of patients with unresectable locally advanced or metastatic TNBC whose tumors have PD-L1 expression >1%, and who have not received prior chemotherapy for metastatic disease. Hepatocellular carcinoma (HCC): •
TECENTRIQ® in combination with Avastin, is indicated for the treatment of patients with unresectable HCC who have not received prior systemic therapy.
Dosage and method of administration
• TECENTRIQ® must be administered as an intravenous infusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus and do not co-administer other medicinal products
through the same infusion line. The initial dose of TECENTRIQ® must be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be administered over 30 minutes.
• The recommended dose of TECENTRIQ® in monotherapy or combination therapy is: 840 mg administered by IV infusion every 2 weeks, or 1200 mg administered by IV infusion every 3 weeks, or 1680 mg administered
by IV infusion every 4 weeks.
• TECENTRIQ® combination therapy: For the use of TECENTRIQ® in combination therapy, please also refer to the full prescribing information for the combination product. TECENTRIQ® should be administered prior to the
combination therapy if given on the same day.
1L non-squamous NSCLC TECENTRIQ® in combination with Avastin, paclitaxel, and carboplatin During the induction phase, TECENTRIQ® is administered according to its dosing schedules by intravenous (IV) infusion, and
Avastin, paclitaxel, and carboplatin are administered every 3 weeks for four or six cycles. The induction phase is followed by a maintenance phase without chemotherapy in which TECENTRIQ® is administered according
to its dosing schedules by IV infusion, and Avastin is administered every 3 weeks. TECENTRIQ® in combination with nab-paclitaxel and carboplatin During the induction phase, TECENTRIQ® is administered according to
its dosing schedules by IV infusion, and nab-paclitaxel and carboplatin are administered every 3 weeks for four or six cycles. For each 21-day cycle, nab-paclitaxel and carboplatin are administered on day 1. In addition,
nab-paclitaxel is administered on days 8 and 15. The induction phase is followed by a maintenance phase without chemotherapy in which TECENTRIQ® is administered according to its dosing schedule.
2
1L ES-SCLC TECENTRIQ® in combination with carboplatin and etoposide During the induction phase, TECENTRIQ® is administered according to its dosing schedules by IV infusion, and carboplatin and etoposide are
administered by IV infusion every three weeks for four cycles. Carboplatin and etoposide are administered on day 1 of each cycle, and etoposide is also administered on days 2 and 3. The induction phaste is followed by
a maintenance phase without chemotherapy in which TECENTRIQ® is administered according to its dosing schedules by IV infusion.
1L TNBC TECENTRIQ® in combination with nab-paclitaxel. TECENTRIQ® is administered according to its dosing schedules by IV infusion and 100 mg/m2 nab-paclitaxel is administered on days 1, 8 and 15 during each 28-day
cycle. Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test (see section 3.1.2 Clinical / Efficacy Studies).
HCC TECENTRIQ® in combination with Avastin. TECENTRIQ® is administered according to its dosing schedules by IV infusion, and Avastin 15 mg/kg is administered every 3 weeks.
The safety and efficacy of alternating or switching between TECENTRIQ® and products that are biosimilar but not deemed interchangeable to TECENTRIQ® has not been established. Therefore, the benefit/risk of
alternating or switching needs to be carefully considered. Safety reporting for potential undesirable effects: Please report any adverse events to the local Roche Adverse Event email at
singapore.drugsafety@roche.com or call (65) 6735 0550. This will enable Roche to better understand the safety of TECENTRIQ®, and to provide appropriate information to Health Authorities, Healthcare Providers
and patients.
References: 1. Gradishar, W. (2020, July 15). NCCN Clinical Practice Guidelines in Oncology - Breast Cancer. Retrieved 2020, from https://www2.tri-kobe.org/nccn/guideline/breast/english/breast.pdf. 2. Emens, LA, et
al. IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab and nab-paclitaxel vs placebo and nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast
cancer. Annals of Oncology (2020) 31 (S4): S1148. doi.org/10.1016/j.annonc.2020.08.2244. 3.TECENTRIQ® Prescribing Information August 2020
Published by Roche Singapore Pte Ltd 1 Paya Lebar Link, # 09-03 PLQ 1 Paya Lebar Quarter, Singapore 408533 Tel: +65 6735 0550 | Fax: +65 6737 5216
For HCPs only
M-SG-00000136-10-2020THE 9TH ASIA-PACIFIC BREAST CANCER VIRTUAL SUMMIT INDUSTRY SATELLITE SYMPOSIUM
Sponsored by Pfizer Oncology
Management of HR+ HER2- mBC:
From Clinical Evidence to Real-World Experience
INVITATION
10 January 2021 18:30–19:15
(Sunday) (GMT+8)
Join regional thought-leaders in exploring key advances
in the field of HR+ HER2- mBC, with a focus on real-world
data of CDK4/6 inhibitors, as well as how to effectively
navigate the mBC patient journey in Asia.
CHAIRPERSON SPEAKERS
Dr Samuel Ow Dr Janice Tsang Dr Shona Nag
Consultant Honorary Clinical Assistant Professor Director of Oncology Services
National University Cancer Institute The University of Hong Kong Sahyadri Group of Hospitals
Singapore Hong Kong Pune, India
AGENDA
Duration Topic Faculty
5 mins Introduction Dr Samuel Ow, Singapore
20 mins Management of HR+ HER2- mBC: Dr Janice Tsang, Hong Kong
From Clinical Evidence to Real-World Experience
15 mins Case Presentation Dr Shona Nag, India
5 mins Q&A Dr Samuel Ow, Singapore
JOIN OUR SYMPOSIUM VISIT OUR PROFILE
Pfizer Private Limited
80 Pasir Panjang Road, #16-81/82, Mapletree Business City, Singapore 117372
Tel: (65) 6403 8888 | Fax: (65) 6403 8868 | www.pfizer.com.sg
This symposium may contain information about investigational product(s)/indication(s) which are yet to be approved in your country.
For healthcare professionals only. More information is available upon request.
PP-IBR-SGP-0066/05JAN2021LIFE
For Healthcare Professionals Only.
Novartis (Singapore) Pte Ltd Please scan this QR code or visit
20 Pasir Panjang Road, #10-25/28 https://www.novartis.com.sg/
Mapletree Business City, Singapore 117439
Phone: +65 6722 6010 • Fax: +65 6323 4335 product-list/kisqali to access the
• www.novartis.com full prescribing information
SG1909734699Inventing for life
MAIN SPONSORS
PLATINUM SPONSORS
SILVER SPONSOR E-PARTNERSSEE YOU AGAIN
IN
2022
APBCS.ORG
INDEX® Conferences & Exhibitions Organization Est.
P.O. Box: 13636 | Dubai-UAE | INDEX Holding Headquarters Road # D-62 | Opposite Nad Al Hamar
Tel: +971 4 5208888 | Fax: +971 4 3384193 | Email: info@apbcs.org
24You can also read
